Cogentus Pharmaceuticals is a company focused on developing prescription pharmaceutical products in North America and Europe.
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 21, 2007 | Series C | $62.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Apothecary Capital | — | Series C |